Bupivacaine Liposome Injection + Bupivacaine Hydrochloride Injection
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Local Analgesia Via Nerve Block
Conditions
Local Analgesia Via Nerve Block
Trial Timeline
Mar 3, 2026 → Nov 1, 2026
NCT ID
NCT06529432About Bupivacaine Liposome Injection + Bupivacaine Hydrochloride Injection
Bupivacaine Liposome Injection + Bupivacaine Hydrochloride Injection is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Local Analgesia Via Nerve Block. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06529432. Target conditions include Local Analgesia Via Nerve Block.
What happened to similar drugs?
6 of 20 similar drugs in Local Analgesia Via Nerve Block were approved
Approved (6) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06529432 | Phase 2 | Recruiting |
Competing Products
20 competing products in Local Analgesia Via Nerve Block